[PMID]: | 8928090 |
[Au] Autor: | De La Cruz JP; Moreno A; Mérida F; García Campos J; Sánchez de la Cuesta F |
[Ad] Endereço: | Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, Spain. |
[Ti] Título: | The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. |
[So] Source: | Thromb Res;81(3):327-37, 1996 Feb 01. |
[Is] ISSN: | 0049-3848 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | We compared the effects of dipyridamole, RA-642, and mopidamol on platelet activity and thromboxane/prostacyclin balance in relation to the degree of retinal vascularization in a model of experimental streptozotocin-induced diabetes in rats. After 3 months, collagen-induced platelet aggregation in whole blood was 25% higher in diabetic animals than in nondiabetics. Dipyridamole inhibited 43% platelet aggregation, mopidamol 39%, and RA-642 36%. Platelet production of thromboxane B2 was 87% higher in untreated diabetic rats. Mopidamol and RA-642 produced a 46% and 41% inhibition of thromboxane B2. Dipyridamole did not inhibited thromboxane B2 synthesis. Aortic production of 6-keto-PGF1 alpha was 43% lower in untreated diabetic animals and showed no change after treatment with either mopidamol or RA-642. In contrast, dipyridamole caused a 90% increase in aortic production of prostacyclin. Computerized analysis of retinal vascularization showed that untreated diabetic rats had a 81% decrease in the area occupied by peroxidase-labelled vessels as compared with nondiabetics. Treatment with dipyridamole, mopidamol, and RA-642 caused 2.5-fold, 2.8-fold and four-fold increases, respectively, in the percentage of retinal surface occupied by peroxidase-labelled vessels. Differences in retinal vascularization between diabetic animals given RA-642 and nondiabetic controls were negligible. |
[Mh] Termos MeSH primário: |
Diabetes Mellitus Experimental/tratamento farmacológico Retinopatia Diabética/prevenção & controle Dipiridamol/farmacologia Mopidamol/farmacologia Inibidores da Agregação de Plaquetas/farmacologia Pirimidinas/farmacologia
|
[Mh] Termos MeSH secundário: |
Animais Glicemia/metabolismo Diabetes Mellitus Experimental/complicações Diabetes Mellitus Experimental/metabolismo Retinopatia Diabética/metabolismo Epoprostenol/metabolismo Masculino Neovascularização Patológica/prevenção & controle Ratos Ratos Wistar Tromboxanos/metabolismo
|
[Pt] Tipo de publicação: | COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T |
[Nm] Nome de substância:
| 0 (Blood Glucose); 0 (Platelet Aggregation Inhibitors); 0 (Pyrimidines); 0 (Thromboxanes); 4Q0IWP8B8O (Mopidamol); 54093-30-0 (RA 642); 64ALC7F90C (Dipyridamole); DCR9Z582X0 (Epoprostenol) |
[Em] Mês de entrada: | 9610 |
[Cu] Atualização por classe: | 131121 |
[Lr] Data última revisão:
| 131121 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 960201 |
[St] Status: | MEDLINE |
|
|